Abstract: A 6-aminopyrazolopyrimidine compound, or a pharmaceutically acceptable salt thereof, having NLRP3 inflammasome inhibitory activity, a pharmaceutical composition comprising the same, and their medical use, etc., are provided. A compound of Formula [IA]: or a pharmaceutically acceptable salt thereof, wherein a partial structure: is a structure of the following formula: etc. wherein R4 is hydrogen or C1-4 alkyl, in which the alkyl may be optionally substituted with hydroxy or cyano, Ring group CyA is a group of the following formula: etc. wherein R6 and R7 are, each independently, hydrogen, hydroxy, cyano, C1-6 alkyl, etc., R8 and R9 are, each independently, hydrogen, C1-4 alkyl, or C1-4 haloalkyl, R10 is hydrogen, cyano, C1-6 alkyl, etc.), R1 is hydrogen or C1-4 alkyl, R2A and R3A are, each independently, hydrogen, C1-6 alkyl etc.

Abstract: A power supply control semiconductor device that generates and outputs a drive pulse to turn on and off a switch, which is configured to intermittently supply a current to a primary winding of a voltage conversion transformer, in response to input of a voltage proportional to the current flowing through the primary winding of the voltage conversion transformer and an output voltage detection signal from a secondary side of the voltage conversion transformer is provided. The power supply control semiconductor device is in a no-lead resin-sealed package. The package includes external terminals including a first terminal as an input terminal, a second terminal provided next to the first terminal, and third terminals that have a lower breakdown voltage relative to the first terminal and are different from the second terminal. An interval between the first terminal and the second terminal is wider than each interval between the third terminals.

Abstract: An acylsulfamide compound, or a pharmaceutically acceptable salt thereof, having NLRP3 inflammasome inhibitory activity, a pharmaceutical composition comprising the same, and their medical use, etc., are provided. A compound of Formula [Ia]: or a pharmaceutically acceptable salt thereof, wherein a partial structure: is: Ring Cy is an optionally substituted heteroaryl or phenyl; RDy and REy are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C1-4 haloalkyl, optionally substituted C3-6 cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl, or alternatively, RDy and REy may combine together with the nitrogen atom to which they attach to form heterocycloalkyl, etc.

Abstract: A power supply control semiconductor device that generates and outputs a drive pulse to turn on and off a switch, which is configured to intermittently supply a current to a primary winding of a voltage conversion transformer, in response to input of a voltage proportional to the current flowing through the primary winding of the voltage conversion transformer and an output voltage detection signal from a secondary side of the voltage conversion transformer is provided. The power supply control semiconductor device is in a no-lead resin-sealed package. The package includes external terminals including a first terminal as an input terminal, a second terminal provided next to the first terminal, and third terminals that have a lower breakdown voltage relative to the first terminal and are different from the second terminal. An interval between the first terminal and the second terminal is wider than each interval between the third terminals.

Abstract: An optical module includes a fixed substrate, and a sensor substrate secured to the fixed substrate and having a through-hole formed therein. A light emitting device is secured to the fixed substrate at a position in the through-hole. A light receiving device is provided in the sensor substrate. A dummy light receiving device is formed between the light receiving device and the through-hole, around the through-hole, and in the sensor substrate. The light receiving device and the dummy light receiving device are made of an impurity diffusion layer having a same conductive type as a conductive type of a surface layer of the sensor substrate. The dummy light receiving device is deeper than the light receiving device.

Abstract: To provide an easy and practical iron ion removal method, as a method for purifying P1,P4-di(uridine 5?-)tetraphosphate from a solution containing iron ions. Purification is performed by a purification method including a method for purifying P1,P4-di(uridine 5?-)tetraphosphate by removing iron ions from an aqueous solution or hydrophilic solvent solution containing P1,P4-di(uridine 5?-)tetraphosphate and iron ions, including (1) a step of purification using a chelating resin packed column, and (2) a step of adjusting the pH of the solution after said purification step using the chelating resin packed column to 5.5 or less, and then crystallizing P1,P4-di(uridine 5?-)tetraphosphate, or a step of treating the solution after said purification step using the chelating resin packed column with zinc chloride-activated activated carbon.

Abstract: An optical module includes a fixed substrate, and a sensor substrate secured to the fixed substrate and having a through-hole formed therein. A light emitting device is secured to the fixed substrate at a position in the through-hole. A light receiving device is provided in the sensor substrate. A dummy light receiving device is formed between the light receiving device and the through-hole, around the through-hole, and in the sensor substrate. The light receiving device and the dummy light receiving device are made of an impurity diffusion layer having a same conductive type as a conductive type of a surface layer of the sensor substrate. The dummy light receiving device is deeper than the light receiving device.

Abstract: [Problem] Provided is a method for easily and stably storing crystals of P1,P4-bis(5?-uridyl)tetraphosphate for a long term. [Solution] A method for storing packed crystals of P1,P4-bis(5?-uridyl)tetraphosphate or a pharmaceutically acceptable salt thereof, wherein one of the following storage conditions (1) to (3): (1) a storage temperature of 0° C. or more and less than 25° C.; (2) a storage temperature of 25° C. or more and less than 40° C. and a crystal pH of 4.5 to 8.0; and (3) a storage temperature of 40° C. or more and less than 60° C. and a crystal pH of 5.0 to 6.4 is selected and the crystals of P1,P4-bis(5?-uridyl)tetraphosphate or the pharmaceutically acceptable salt thereof are stored under the selected condition.

Abstract: To provide an easy and practical iron ion removal method, as a method for purifying P1,P4-di(uridine 5?-)tetraphosphate from a solution containing iron ions. Purification is performed by a purification method including a method for purifying P1,P4-di(uridine 5?-)tetraphosphate by removing iron ions from an aqueous solution or hydrophilic solvent solution containing P1,P4-di(uridine 5?-)tetraphosphate and iron ions, including (1) a step of purification using a chelating resin packed column, and (2) a step of adjusting the pH of the solution after said purification step using the chelating resin packed column to 5.5 or less, and then crystallizing P1,P4-di(uridine 5?-)tetraphosphate, or a step of treating the solution after said purification step using the chelating resin packed column with zinc chloride-activated activated carbon.

Abstract: A battery protecting apparatus includes: a charging/discharging control chip including a charging control FET and a discharging control FET connected to a secondary battery; a protecting chip configured to control, based on a voltage between both ends of the secondary battery, the FETs to prevent overcharging, over discharging, and an overcurrent; and a lead frame having a connection surface for a plurality of external terminals and another surface in conduction with the connection surface. Said another surface is electrically connected, via a conductive material, to terminals of the FETs formed on a front surface of the charging/discharging control chip. A back surface of the protecting chip faces a back surface of the charging/discharging control chip via an insulative member. Terminals of the protecting chip are electrically connected to said another surface through bonding wires. The charging/discharging control chip and the protecting chip are covered by a resin.

Abstract: [Problem] Provided is a method for easily and stably storing crystals of P1, P4-bis(5?-uridyl)tetraphosphate for a long term. [Solution] A method for storing packed crystals of P1, P4-bis(5?-uridyl)tetraphosphate or a pharmaceutically acceptable salt thereof, wherein one of the following storage conditions (1) to (3): (1) a storage temperature of 0° C. or more and less than 25° C.; (2) a storage temperature of 25° C. or more and less than 40° C. and a crystal pH of 4.5 to 8.0; and (3) a storage temperature of 40° C. or more and less than 60° C. and a crystal pH of 5.0 to 6.4 is selected and the crystals of P1, P4-bis (5?-uridyl) tetraphosphate or the pharmaceutically acceptable salt thereof are stored under the selected condition.

Abstract: A battery protecting apparatus includes: a charging/discharging control chip including a charging control FET and a discharging control FET connected to a secondary battery; a protecting chip configured to control, based on a voltage between both ends of the secondary battery, the FETs to prevent overcharging, over discharging, and an overcurrent; and a lead frame having a connection surface for a plurality of external terminals and another surface in conduction with the connection surface. Said another surface is electrically connected, via a conductive material, to terminals of the FETs formed on a front surface of the charging/discharging control chip. A back surface of the protecting chip faces a back surface of the charging/discharging control chip via an insulative member. Terminals of the protecting chip are electrically connected to said another surface through bonding wires. The charging/discharging control chip and the protecting chip are covered by a resin.

Abstract: Provided is a compound or a salt thereof, which has an excellent JAK inhibitory action, and is useful as a prophylactic or therapeutic agent for autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's syndrome, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: Provided is a compound or a salt thereof, which has an excellent JAK inhibitory action, and is useful as a prophylactic or therapeutic agent for autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's syndrome, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Abstract: FRET measurement uses a FRET probe that includes a probe element X containing a donor fluorescent substance and a probe element Y containing an acceptor fluorescent substance and enables FRET to occur when the probe element X and the probe element Y approach to each other or bind together. The modulation frequency of laser light with which the FRET probe is irradiated is adjusted to an optimum modulation frequency that maximizes a difference between the phase difference of donor fluorescence emitted from the donor fluorescent substance with respect to intensity modulation of the laser light at the time when FRET occurs and the phase difference of donor fluorescence emitted from the donor fluorescent substance with respect to intensity modulation of the laser light at the time when FRET does not occur.

Abstract: Provided is a compound or a salt thereof, which has an excellent JAK inhibitory action, and is useful as a prophylactic or therapeutic agent for autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's syndrome, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Abstract: Provided is a compound having a superior FLAP inhibitory action and useful as a prophylactic or therapeutic agent for arteriosclerosis and the like, and a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present DESCRIPTION, or a salt thereof.

Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.